Prospective, In-Vivo, Post-Market Safety and Efficacy Surveillance Registry of the MAXX Orthopedics, Freedom Total Knee® System

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMaxx Orthopedics Inc

About this trial

In an effort to satisfy regulatory requirements for post-market surveillance of product safety and efficacy, a representative sample of patients will be recruited for prospective monitoring.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient is > 18 years of age

Patient has failed attempts at non-operative conservative therapy

Patient has participated in the informed consent process and signed an IRB approved informed consent

Patient is scheduled to undergo unilateral or bilateral primary TKA of the knee

Disqualifiers

Patients with previous TKA, UKA, HTO or knee fusion of the indicated knee

Patients that have undergone previous surgery of indicated knee for tumor, trauma or fracture

Evidence of active or suspected (systemic or local) infection at time of surgery

Other significant disabling problems from the musculoskeletal system than in the knee (i.e.: muscular dystrophy, polio, neuropathic joints)

Trial population

The registry population will consist of adult male and female subjects who are suffering from moderate to severe symptoms of the following diagnoses: painful degenerative knee disease.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Total Knee Arthroplasty

    Device

    Post-Market Surveillance of the Freedom Total Knee System for Primary TKA

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: Patients receiving the Maxx Freedom Total Knee System for primary TKA1 intervention

Trial outcomes

Primary outcomes

1

Device Survivorship

Revision / re-operation post-operatively due to device / device composite failure. An anticipated benefit of the device is that it is more conforming at higher degrees of flexion, which could potentially result in reduced polyethylene wear and improved survivorship over the longer-term. To assess this aspect of the device in addition to safety over the short-, intermediate- and long-term, survivorship analyses will be conducted at the targeted follow-up landmark timepoints. There will be 3 survivorship endpoints: * Revision of any component (including insert) for any reason * Revision of any component (including insert) for any reason except infection

Time frame
2 years

Secondary outcomes

1

Original Knee Society Scale (KSS)

The Knee Society Score rating system was first introduced during the late 1980's and has become the standard clinical evaluation system for reporting results for patients undergoing Total Knee Arthroplasty. Most major journals strongly encourage that total knee manuscripts include Knee Society Score rating scores as part of the result section. The Knee Society Score consists of points given for pain, range of motion, and stability. The Function Score consists of points given for the ability to walk on level surfaces, and the ability to ascend and descend stairs, with deductions for the use of external supporting devices.

Time frame
3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months
2

Knee Injury and Osteoarthritis Outcome Score - Joint Replacement (KOOS-JR)

The KOOS-JR is self-administered and assesses three domains: stiffness (1 question), pain (4 questions), function / daily living (2 questions). The KOOS-JR meets basic criteria of outcome measures and can be used to evaluate the course of knee injury and treatment outcome. Each item (questions) is coded from 0 to 4. The raw responses are summed (0-28) which is then converted to an interval score based on the KOOS-JR conversion table. The score is a percentage score from 0 to 100, 0 representing total knee disability and 100 representing perfect knee health.

Time frame
3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months
3

Patient Reported Outcomes Measurement Information System (PROMIS Global-10)

The Patient Reported Outcomes Measurement Information System (PROMIS Global-10) is a valid and reliable patient assessment and consists of ten (10) items that measure physical health, physical functioning, general mental health, emotional distress, satisfaction with social activities and relationships, ability to carry out usual social activities and roles, pain, fatigue and overall quality of life. The response options are presented as 5-point (as well as a single 11-point) rating scales. The results of the questions are used to calculate two summary scores: a Global Physical Health Score and a Global Mental Health score. These scores are then standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient. The PROMIS 10 scores are predictive of healthcare utilization, mortality in general and disease-specific clinical populations.

Time frame
3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months
4

Visual Analog Scale (VAS)

This scale has been designed to give subjective pain information as to the degree of knee pain you the patient is currently experiencing. VAS scoring is included in the PROMIS GLOBAL-10 assessment and is not necessary to collect a separate assessment. Applying the VAS, the patient will select a number from 1 (no pain) to 10 (maximum pain) that most closely describes their current pain.

Time frame
3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months

Other outcomes

1

Radiography (plain-film radiography as per standard of care - independent collective site assessment)

* Evidence of correct component position * Evidence of stable component fixation * Review of incidence and location of any lucencies, sclerotic lines, component subsidence and/or osteolysis

Time frame
3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months
2

Adverse Events

* Local (wound and skin) * Systemic (infection markers) * Clinical / radiographic evidence of component / composite failure * Unscheduled re-visit or re-operation within 24 months post-operatively.

Time frame
3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.